Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Lenvima-Keytruda for HCC Misses PIII Primary Goal: Eisai/Merck
The combination therapy of Eisai’s orally administered tyrosine kinase inhibitor Lenvima (lenvatinib) and US Merck’s PD-1 inhibitor Keytruda (pembrolizumab) failed to meet the primary endpoints in a PIII trial, dubbed LEAP-002, targeting patients with unresectable hepatocellular carcinoma (HCC), the two…
To read the full story
Related Article
- Lenvima-Keytruda Combo’s Liver Cancer Trial Halted after OS Miss
October 31, 2025
BUSINESS
- Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
August 20, 2026
- Biogen Japan President Den Tapped as Chief of Staff to Global CEO
August 20, 2026
- Moderna’s mNEXSPIKE Grabs Japan Approval for XFG Variant
August 20, 2026
- Nipro’s Forxiga AG to Hit Shelves on September 4
August 20, 2026
- Teijin Taps CAR-T Expert Campana as Technical Advisor
August 20, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…